Interaction Checker

Pamidronate interactions

Pamidronate (Aredia), a bisphosphonate has 71 documented interactions across the FDA labels and fact sheets we index: 4 major, 35 moderate, 1 minor, and 31 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (4)

  • AlendronatebisphosphonateMajor

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (Pamidronate label, Contraindications)

  • IbandronatebisphosphonateMajor

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (Pamidronate label, Contraindications)

  • RisedronatebisphosphonateMajor

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (Pamidronate label, Contraindications)

  • Zoledronic acidbisphosphonateMajor

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (Pamidronate label, Contraindications)

Moderate interactions (35)

  • Azelastine and fluticasoneantihistamineModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • BeclomethasonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • BetamethasonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • BudesonidecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • Calcipotrienevitamin D analogModerate

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (Pamidronate label, Warnings and precautions)

  • Calcitriolvitamin D analogModerate

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (Pamidronate label, Warnings and precautions)

  • CalciumVitamin and mineralModerate

    Calcium binds these drugs in the gut and can sharply cut how much is absorbed; separate the doses. (NIH Office of Dietary Supplements, Calcium)

  • CapecitabineantimetaboliteModerate

    Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (Capecitabine label, Drug interactions)

  • CiclesonidecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • ClobetasolcorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • Deferasiroxiron supplementModerate

    The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (Deferasirox label, Warnings and precautions)

  • DeflazacortcorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • DesonidecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • DexamethasonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • Doxercalciferolvitamin D analogModerate

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (Pamidronate label, Warnings and precautions)

  • FludrocortisonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • FlunisolidecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • FluocinonidecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • FluticasonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • HalobetasolcorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • HydrocortisonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • IronVitamin and mineralModerate

    Iron binds these drugs in the gut and reduces their absorption; separate the doses. (NIH Office of Dietary Supplements, Iron)

  • MagnesiumVitamin and mineralModerate

    Magnesium-containing supplements and antacids reduce absorption of these drugs; separate the doses by at least two hours. (NIH Office of Dietary Supplements, Magnesium)

  • MethylprednisolonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • MometasonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • Olopatadine and mometasoneantihistamineModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • OxybutyninanticholinergicModerate

    Oxybutynin chloride extended-release tablets should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis. (Oxybutynin label, Warnings and precautions)

  • Paricalcitolvitamin D analogModerate

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (Pamidronate label, Warnings and precautions)

  • PrednisolonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • PrednisonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • SunitinibModerate

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (Sunitinib label, Warnings and precautions)

  • TriamcinolonecorticosteroidModerate

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Pamidronate label, Warnings and precautions)

  • Vitamin DVitamin and mineralModerate

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (Pamidronate label, Warnings and precautions)

Minor mentions (1)

  • Exemestanearomatase inhibitorMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (Exemestane label, Warnings and precautions)

No significant interaction reported (31)

  • Acetazolamidecarbonic anhydrase inhibitorNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Amiloridepotassium-sparing diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Atenolol and chlorthalidonebeta blockerNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Benazepril and hydrochlorothiazideACE inhibitorNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Bisoprolol and hydrochlorothiazidebeta blockerNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Bumetanideloop diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Candesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)No interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Chlorothiazidethiazide diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Chlorthalidonethiazide diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Enalapril and hydrochlorothiazideACE inhibitorNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Eplerenonealdosterone antagonistNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Ethacrynic acidloop diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Fosinopril and hydrochlorothiazideACE inhibitorNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Furosemideloop diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Hydrochlorothiazidethiazide diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Indapamidethiazide diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Irbesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)No interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Lisinopril and hydrochlorothiazideACE inhibitorNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Losartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)No interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Metolazonethiazide diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Metoprolol and hydrochlorothiazidebeta blockerNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Olmesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)No interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)No interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Quinapril and hydrochlorothiazideACE inhibitorNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Spironolactonealdosterone antagonistNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Spironolactone and hydrochlorothiazidealdosterone antagonistNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Telmisartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)No interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Torsemideloop diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Triamterenepotassium-sparing diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Triamterene and hydrochlorothiazidepotassium-sparing diureticNo interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

  • Valsartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)No interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronate label, Drug interactions)

Check Pamidronate against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.